Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1171-1174

  Brynskov, Troels ^a,b   Laugesen, Caroline Schmidt ^a   Halborg, Jakob ^a   Kemp, Henrik ^a   Sørensen, Torben Lykke ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Intravitreal dexamethasone implant; Irvine Gass syndrome; Ozurdex ; Pseudophakic cystoid macular edema

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CASE REPORT; DISEASE DURATION; DRUG IMPLANT; DRUG RESPONSE; HUMAN; MALE; METAMORPHOSIS; PATIENT MONITORING; PSEUDOPHAKIC CYSTOID MACULAR EDEMA; REMISSION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84879142424     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46399     Document Type: Article

References (11)

1. Arevalo JF, Maia M, Garcia-Amaris RA, et al; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009;116:1481-1487.
2. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-146.
3. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138(6): 1046-1048.
4. Barone A, Russo V, et al; Short-term safety and effcacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina. 2009;29(1):33-37.
5. Demirel S, Batioglu F, Özmert E. Intravitreal ranibizumab for the treatment of cystoid macular edema in Irvine-Gass syndrome. J Ocul Pharmacol Ther. 2012;28(6):636-639.
6. Mason JO III, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
7. Spitzer MS, Ziemssen F, Yoeruek, et al; Effcacy of intravitreal bevaci-zumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg. 2008;34(1):70-75.
8. Sørensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triam-cinolone for macular oedema: effcacy in relation to aetiology. Acta Ophthalmol Scand. 2004;83(1):67-70.
9. Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1152-1159.
10. Williams GA, Haller JA, Kuppermann BD, et al; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048-1054.
11. Meyer LM, Schönfeld CL. Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol. 2011;2(3):319-322.